^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
LymphoTrack® Dx IGH Assay

Type:
Laboratory Developed Test
Related tests:
Evidence

News

1m
Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma. (PubMed, Discov Oncol)
"Compared with NGF, NGS exhibits higher sensitivity and reproducibility in MRD detection and can be an effective strategy for MRD monitoring in Chinese MM patients."
Journal • Minimal residual disease
|
IGH (Immunoglobulin Heavy Locus)
|
LymphoTrack® Dx IGH Assay
2ms
Pivotal, Clinical Study for the Accuracy Evaluation of the IdentiClone Dx IGH Assay (clinicaltrials.gov)
P=N/A, N=250, Recruiting, Invivoscribe, Inc. | Not yet recruiting --> Recruiting
Enrollment open
|
LymphoTrack® Dx IGH Assay
2ms
SKY92 Molecular Profiling in Combination With MRD Risk Profiling to Identify High-Risk Multiple Myeloma Patients in Ireland (SKIP-MM) (EACR-AACR 2024)
We continue to evaluate the clinical significance of SKY92 in combination with MRD testing as a superior prognostic repertoire of testing. These methods will improve risk stratification, and in future aid with risk-adapted therapy approaches.
Combination therapy • Clinical
|
Chr t(4;14)
|
LymphoTrack® Dx IGH Assay
2ms
GENETIC PREDICTORS OF PROGNOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHTS FROM NEXT-GENERATION SEQUENCING (EBMT 2024)
Our analysis revealed that specific genetic mutations and chromosomal alterations are strongly associated with the disease's course and patient prognosis. Particularly, the presence of unmutated IGHV and TP53 mutations emerged as key indicators of a more aggressive disease course and shorter treatment-free intervals. These findings underscore the critical role of advanced genetic testing in identifying patients who may require more intensive treatment and monitoring.
IO biomarker • Next-generation sequencing
|
IGH (Immunoglobulin Heavy Locus) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
|
TP53 mutation • Chr del(17p) • Chr del(11q) • Chr del(17p) + Chr del(11q) • TS 12
|
LymphoTrack® Dx IGH Assay • SureSeq™ CLL + CNV Panel
5ms
Next-Generation Sequencing of Vitreoretinal Lymphoma by Vitreous Liquid Biopsy: Diagnostic Potential and Genotype/Phenotype Correlation. (PubMed, Invest Ophthalmol Vis Sci)
Overall, NGS of the vitreous demonstrated high sensitivity among conventional diagnostic tests. VRL and CNSL appeared to have both shared and distinct genetic variations, which may suggest site-specific variations from a common origin.
Journal • Liquid biopsy • Next-generation sequencing • Biopsy
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IGH (Immunoglobulin Heavy Locus) • ETV6 (ETS Variant Transcription Factor 6) • IL6 (Interleukin 6) • IL10 (Interleukin 10) • PIM1 (Pim-1 Proto-Oncogene) • IGLL5 (Immunoglobulin Lambda Like Polypeptide 5)
|
MYD88 mutation • MYD88 L265P
|
LymphoTrack® Dx IGH Assay • LymphoTrack® Dx IGK Assay
6ms
New trial
|
LymphoTrack® Dx IGH Assay
7ms
Single-Step IGHV Next-Generation Sequencing Detects Clonality and Somatic Hypermutation in Lymphoid Malignancies: A Phase III Diagnostic Accuracy Study. (PubMed, Cancers (Basel))
Overall, conventional Sanger sequencing and next-generation-sequencing-based clonality and somatic hypermutation analyses gave comparable results. For future use in a routine diagnostic workflow, NGS-based approaches should be evaluated prospectively and an analysis of cost-effectiveness should be performed.
Journal • P3 data • Next-generation sequencing
|
IGH (Immunoglobulin Heavy Locus)
|
LymphoTrack® Dx IGH Assay
11ms
Minimal/measurable residual disease (MRD) monitoring in patients with lymphoid neoplasms by high-throughput sequencing of the T-cell receptor. (PubMed, J Mol Diagn)
This assay demonstrated excellent test performance characteristics, achieving a sensitivity of 1 out of 100,000 T-cell equivalents for the DNA inputs evaluated and high concordance with orthogonal testing methods. This assay was further utilized to correlate disease burden in several patients, demonstrating its potential utility for monitoring patients with T-cell malignancies.
Journal
|
LymphoTrack® Dx IGH Assay
12ms
MEASUREMENT OF INTRACLONAL DIVERSIFICATION REFINES THE PROGNOSTIC IMPACT OF IGHV MUTATIONS IN CLL (EHA 2023)
Here we report a novel UMI-independent method to assess ID in CLL. By applying this approach, we provide evidence that: i) ID prevalently affects M-CLL; ii) patients affected by M-CLL with ID have better outcome than M- CLL cases without ID; iii) ID identifies a subset of M-CLL with specific molecular/biological features and clinicalcharacteristics. IGH, Prognostic factor, Chronic lymphocytic leukemia
IGH (Immunoglobulin Heavy Locus) • ITGA4 (Integrin, alpha 4)
|
IGH mutation
|
LymphoTrack® Dx IGH Assay
12ms
NON-INVASIVE MINIMAL RESIDUAL DISEASE ANALYSIS BY IMMUNOGLOBULIN GENE REARRANGEMENTS ON CIRCULATING TUMOR DNA PREDICTS THE OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (EHA 2023)
A multicenter cohort of 53 consecutive newly diagnosed DLBCL treated with R-CHOP was included in this study... In most DLBCL patients at diagnosis, ctDNA was suitable for IG-based biomarker identification by NGS and was comparable to diagnostic LN biopsies. ctDNA MRD evaluation both at interim and at EOT allowed to predict theoutcome of DLBCL patients. ctDNA MRD can refine the CT/PET-CT-based response.
Clinical • Minimal residual disease • Circulating tumor DNA
|
LymphoTrack® Dx IGH Assay • LymphoTrack® Dx IGK Assay
|
Rituxan (rituximab)
1year
COMBINING SKY92 GENE EXPRESSION PROFILING AND IGH CLONALITY TO EVALUATE GENETIC RISK IN IRISH MULTIPLE MYELOMA PATIENTS (EMN 2023)
Future work will aim to evaluate the achievement of MRD negativity based on SKY92 status, and whether this impacts survival. We will continue to profile Irish patients and ultimately, we hope this could lead to a more risk-stratified treatment approach.
Clinical
|
SDC1 (Syndecan 1)
|
Chr t(11;14) • Chr t(4;14) • Chr t(14;16)
|
LymphoTrack® Dx IGH Assay
1year
Clonal B-cell expansion and the potential challenges to blood-based early cancer detection (AACR 2023)
A large fraction of NC samples (15%) had evidence of expanded lymphoid clones with SHM. The PTR of the top clone underscores the higher frequency of CE associated with increased age in asymptomatic participants. Clonal expansion of blood cell lineages can also carry genetic or epigenetic alterations that are similar to those associated with non-hematologic cancers.
LymphoTrack® Dx IGH Assay
over1year
Clinical implication of minimal residual disease assessment by next-generation sequencing-based immunoglobulin clonality assay in pediatric B-acute lymphoblastic leukemia. (PubMed, Front Oncol)
"Our study demonstrated that MRD assessment by NGS-based Ig clonality assay could be applied in most pediatric B-ALL patients. Normalized post-induction MRD <0.01% was a significant prognostic indicator."
Journal • Minimal residual disease
|
LymphoTrack® Dx IGH Assay • LymphoTrack® Dx IGK Assay
over2years
NGS Clonality Assessment Shows that Many Synchronous or Metachronous PTLD Lesions are Clonally Distinct if EBV-Positive but Often Clonally Related if EBV-Negative (USCAP 2022)
"NGS clonality studies reveal that patients with >1 PTLD lesion often, but not always, demonstrate clonally unrelated lesions, when they are all EBV+, whether these lesions are seeming relapses or present without intervening remissions. Recurrent or multiple EBV- lesions appear to more often represent clonally related lesions, the expectation with lymphomas in immunocompetent hosts. Better understanding of clonal relationship in synchronous or metachronous PTLD cases may eventually lead to different therapeutic approaches in EBV+ and EBV- lesions."
LymphoTrack® Dx IGH Assay
over2years
[VIRTUAL] Clinical Implication of Immunoglobulin Gene-Based Minimal Residual Disease Monitoring by Next-generation Sequencing in Pediatric Acute Lymphoblastic Leukemia (ICBMT 2021)
Conclusion : Our study shows that, Ig-based MRD by NGS could be applied in most pediatric B-ALL patients in clinic. Normalization as % of TNC was significant to implicate the MRD as a valuable prognostic.
Clinical • Next-generation sequencing • Minimal residual disease
|
CD19 positive
|
LymphoTrack® Dx IGH Assay
over3years
[VIRTUAL] Next-Generation Sequencing Minimal Residual Disease of Mantle Cell Lymphoma in Autologous Stem Cell Grafts and Its Implication on Tumor Recurrence (ASH 2020)
Higher MRD loads correlated with inferior post-ASCT PFS and OS. The implication of recombined VDJ stereotypes and their impact on ASCT outcomes warrants further investigation.
Next-generation sequencing
|
LymphoTrack® Dx IGH Assay